Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
20 hedge funds and large institutions have $987K invested in Evoke Pharma in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.2% less ownership
Funds ownership: 6.27% → 6.07% (-0.2%)
13% less capital invested
Capital invested by funds: $1.13M → $987K (-$143K)
13% less funds holding
Funds holding: 23 → 20 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cornerstone Capital
Palo Alto,
California
|
+$36.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.1K |
| 4 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
+$6.06K |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$48K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15K |
| 3 |
Renaissance Technologies
New York
|
-$9.57K |
| 4 |
Jane Street
New York
|
-$8K |
| 5 |
VF
Virtu Financial
New York
|
-$6.94K |
EVOK Hedge Fund Activity: Q1 2022 in Review
20 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2022, worth a combined $987K — down 13% from $1.13M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EVOK and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Cornerstone Capital, opening a new position worth an estimated $36.5K. The largest seller was Sabby Management, exiting entirely with an estimated $48K sold.
- 20 institutional investors held Evoke Pharma (EVOK) as of Q1 2022, down from 23 in Q4 2021.
- Funds reported $987K of Evoke Pharma stock for Q1 2022, down 13% quarter-over-quarter.
- 2 funds opened new Evoke Pharma positions in Q1 2022 and 5 closed out, a net change of -3 holders.
- The largest Evoke Pharma buyer in Q1 2022 was Cornerstone Capital, an estimated $36.5K added.
- The largest Evoke Pharma seller in Q1 2022 was Sabby Management, an estimated $48K sold.
Based on aggregated 13F filings for Q1 2022.